XTX-301 is under clinical development by Xilio Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XTX-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XTX-301 is under development for treatment of solid tumors including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC), MSI-H/dMMR colorectal cancer, MSI-H/dMMR endometrial cancer, prostate cancer, ovarian cancer, pancreatic cancer, and microsatellite stable colorectal cancer. The drug candidate comprises of long-acting, tumour selective interleukin-12. The drug candidate is developed based on Aklusion and Switchblade platform technology.
Xilio Therapeutics overview
Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.
For a complete picture of XTX-301’s drug-specific PTSR and LoA scores, buy the report here.